1
|
Tsigkas G, Apostolos A, Chlorogiannis DD, Bousoula E, Vasilagkos G, Tsalamandris S, Tsiafoutis I, Katsanos K, Toutouzas K, Aminian A, Alexopoulos D, Davlouros P. Thirty-Days versus Longer Duration of Dual Antiplatelet Treatment after Percutaneous Coronary Interventions with Newer Drug-Eluting Stents: A Systematic Review and Meta-Analysis. Life (Basel) 2023; 13:666. [PMID: 36983821 PMCID: PMC10056726 DOI: 10.3390/life13030666] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2022] [Revised: 01/21/2023] [Accepted: 02/24/2023] [Indexed: 03/04/2023] Open
Abstract
Abbreviation of the duration of dual antiplatelet therapy (DAPT) (one or three months) has been recently proposed, especially for high bleeding risk patients, after percutaneous coronary intervention (PCI) with drug-eluting stent (DES). Three databases were screened for eligible randomized control trials. The primary endpoint was the incidence of net adverse clinical events (NACE). Secondary endpoints consisted of major adverse cardiovascular events (MACE), all-cause and cardiovascular mortality, myocardial infarction, stroke, stent-thrombosis, repeat revascularization and major bleeding. We included four RCTs with a total of 26,576 patients; 13,282 patients were grouped in 30-days DAPT, while the remaining 13,294 were allocated in a longer period of DAPT. One month of DAPT did not significantly reduce NACE (odds ratio [OR]: 0.87, 95% confidence intervals [Cl]: 0.74-1.03); however, major bleedings were significantly reduced by 22% (OR: 0.78, 95% Cl: 0.65-0.94). Mortality or ischemic events (stroke, myocardial infarction, revascularization and stent thrombosis) were not affected. Thus, 30-days DAPT could be considered as safe and feasible after PCI with DES in selected patients, especially those with high bleeding risk. Forthcoming RCTs could shed light on the optimal duration of DAPT.
Collapse
Affiliation(s)
- Grigorios Tsigkas
- Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece
| | - Anastasios Apostolos
- Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece
- First Department of Cardiology, University of Athens, Hippokration General Hospital, 115 27 Athens, Greece
| | | | - Elena Bousoula
- Department of Cardiology, General Hospital of Piraeus “Tzaneio”, 185 36 Piraeus, Greece
| | - Georgios Vasilagkos
- Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece
| | - Sotirios Tsalamandris
- First Department of Cardiology, University of Athens, Hippokration General Hospital, 115 27 Athens, Greece
| | - Ioannis Tsiafoutis
- First Department of Cardiology, Red Cross Hospital, 115 26 Athens, Greece
| | - Konstantinos Katsanos
- Department of Radiology, School of Medicine, University of Patras, 265 04 Patras, Greece
| | - Konstantinos Toutouzas
- First Department of Cardiology, University of Athens, Hippokration General Hospital, 115 27 Athens, Greece
| | - Adel Aminian
- Department of Cardiology, Centre Hospitalier Universitaire de Charleroi, 6042 Charleroi, Belgium
| | - Dimitrios Alexopoulos
- Second Department of Cardiology, University of Athens, Attikon University Hospital, 124 62 Athens, Greece
| | - Periklis Davlouros
- Department of Cardiology, University Hospital of Patras, 265 04 Patras, Greece
| |
Collapse
|